{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:52Z","timestamp":1790352232947,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFE0131700"],"award-info":[{"award-number":["2022YFE0131700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC3602000"],"award-info":[{"award-number":["2022YFC3602000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing sci-Tech Program","award":["Z191100006619114"],"award-info":[{"award-number":["Z191100006619114"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071813\uff0c8227183"],"award-info":[{"award-number":["82071813\uff0c8227183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10067-024-06992-7","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T11:01:58Z","timestamp":1716202918000},"page":"2229-2236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2735-0658","authenticated-orcid":false,"given":"Jirong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiurong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"6992_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","volume":"16","author":"L Pan","year":"2020","unstructured":"Pan L, Lu MP, Wang JH, Xu M, Yang SR (2020) Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr 16:19\u201330. https:\/\/doi.org\/10.1007\/s12519-019-00229-3","journal-title":"World J Pediatr"},{"key":"6992_CR2","doi-asserted-by":"publisher","first-page":"569234","DOI":"10.3389\/fimmu.2020.569234","volume":"11","author":"OP Rekvig","year":"2020","unstructured":"Rekvig OP (2020) Autoimmunity and SLE: factual and semantic evidence-based critical analyses of definitions, etiology, and pathogenesis. Front Immunol 11:569234. https:\/\/doi.org\/10.3389\/fimmu.2020.569234","journal-title":"Front Immunol"},{"key":"6992_CR3","unstructured":"Justiz VA, Goyal A, Varacallo M (2023) Systemic lupus erythematosus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan"},{"key":"6992_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.20548","volume":"51","author":"GS Alarc\u00f3n","year":"2004","unstructured":"Alarc\u00f3n GS, Mcgwin GJ, Roseman JM, Uribe A, Fessler BJ, Bastian HM, Friedman AW, Baethge B, Vil\u00e1 LM, Reveille JD (2004) Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis Rheum 51:609\u2013615. https:\/\/doi.org\/10.1002\/art.20548","journal-title":"Arthritis Rheum"},{"key":"6992_CR5","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https:\/\/doi.org\/10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"key":"6992_CR6","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, S\u00e1nchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AJ, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, Mcgwin GJ, Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"key":"6992_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","volume":"7","author":"F Basta","year":"2020","unstructured":"Basta F, Fasola F, Triantafyllias K, Schwarting A (2020) Systemic Lupus Erythematosus (SLE) therapy: the old and the new. Rheumatol Ther 7:433\u2013446. https:\/\/doi.org\/10.1007\/s40744-020-00212-9","journal-title":"Rheumatol Ther"},{"key":"6992_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1176\/appi.ajp.2014.13091264","volume":"171","author":"LL Judd","year":"2014","unstructured":"Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender BG, Bulloch K, Cidlowski JA, de Kloet ER, Fardet L, Jo\u00ebls M, Leung DY, Mcewen BS, Roozendaal B, Van Rossum EF, Ahn J, Brown DW, Plitt A, Singh G (2014) Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry 171:1045\u20131051. https:\/\/doi.org\/10.1176\/appi.ajp.2014.13091264","journal-title":"Am J Psychiatry"},{"key":"6992_CR9","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M (2019) Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 393:2332\u20132343. https:\/\/doi.org\/10.1016\/S0140-6736(19)30237-5","journal-title":"Lancet"},{"key":"6992_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40259-013-0015-8","volume":"27","author":"PR Harvey","year":"2013","unstructured":"Harvey PR, Gordon C (2013) B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs 27:85\u201395. https:\/\/doi.org\/10.1007\/s40259-013-0015-8","journal-title":"BioDrugs"},{"key":"6992_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/CMR.00046-17","volume":"30","author":"J Sakai","year":"2017","unstructured":"Sakai J, Akkoyunlu M (2017) The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev 30:991\u20131014. https:\/\/doi.org\/10.1128\/CMR.00046-17","journal-title":"Clin Microbiol Rev"},{"key":"6992_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0961203315608254","volume":"25","author":"DC Salazar-Camarena","year":"2016","unstructured":"Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Mu\u00f1oz-Valle JF, Orozco-L\u00f3pez M, Mar\u00edn-Rosales M, Palafox-S\u00e1nchez CA (2016) Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus 25:582\u2013592. https:\/\/doi.org\/10.1177\/0961203315608254","journal-title":"Lupus"},{"key":"6992_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/art.39809","volume":"69","author":"C Gordon","year":"2016","unstructured":"Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D (2016) Post hoc analysis of the phase II\/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol 69:122\u2013130. https:\/\/doi.org\/10.1002\/art.39809","journal-title":"Arthritis Rheumatol"},{"key":"6992_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coi.2021.06.004","volume":"71","author":"U Salzer","year":"2021","unstructured":"Salzer U, Grimbacher B (2021) TACI deficiency - a complex system out of balance. Curr Opin Immunol 71:81\u201388. https:\/\/doi.org\/10.1016\/j.coi.2021.06.004","journal-title":"Curr Opin Immunol"},{"key":"6992_CR15","doi-asserted-by":"publisher","unstructured":"Garcia-Carmona Y, Cols M, Ting AT, Radigan L, Yuk FJ, Zhang L, Cerutti A, Cunningham-Rundles C\u00a0(2015) Differential induction of plasma cells by isoforms of human TACI. Blood 1749\u20131758. https:\/\/doi.org\/10.1182\/blood-2014-05","DOI":"10.1182\/blood-2014-05"},{"key":"6992_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","volume":"71","author":"R Cornelis","year":"2021","unstructured":"Cornelis R, Chang HD, Radbruch A (2021) Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells. Curr Opin Immunol 71:97\u2013102. https:\/\/doi.org\/10.1016\/j.coi.2021.06.012","journal-title":"Curr Opin Immunol"},{"key":"6992_CR17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/eji.200636800","volume":"37","author":"N Katsenelson","year":"2007","unstructured":"Katsenelson N, Kanswal S, Puig M, Mostowski H, Verthelyi D, Akkoyunlu M (2007) Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol 37:1785\u20131795. https:\/\/doi.org\/10.1002\/eji.200636800","journal-title":"Eur J Immunol"},{"key":"6992_CR18","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40262-014-0175-9","volume":"53","author":"X Chen","year":"2014","unstructured":"Chen X, Hou Y, Jiang J, Zhao Q, Zhong W, Wang W, Yao X, Li L, Fang J, Zhang F, Hu P (2014) Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis. Clin Pharmacokinet 53:1033\u20131044. https:\/\/doi.org\/10.1007\/s40262-014-0175-9","journal-title":"Clin Pharmacokinet"},{"key":"6992_CR19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcph.686","volume":"56","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen X, Hou Y, Jiang J, Zhong W, Yao X, Wang W, Li L, Fang J, Zhang F, Hu P (2016) Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol 56:948\u2013959. https:\/\/doi.org\/10.1002\/jcph.686","journal-title":"J Clin Pharmacol"},{"issue":"339\u2013341","key":"6992_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/096120339300200512","volume":"2","author":"J Font","year":"1993","unstructured":"Font J, Cervera R (1993) 1982 revised criteria for classification of systemic lupus erythematosus\u2013ten years later. Lupus 2(339\u2013341):343. https:\/\/doi.org\/10.1177\/096120339300200512","journal-title":"Lupus"},{"key":"6992_CR21","unstructured":"WHO (2011) Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization, Geneva, 11"},{"key":"6992_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.autrev.2015.02.008","volume":"14","author":"F Ceccarelli","year":"2015","unstructured":"Ceccarelli F, Perricone C, Massaro L, Cipriano E, Alessandri C, Spinelli FR, Valesini G, Conti F (2015) Assessment of disease activity in systemic lupus erythematosus: lights and shadows. Autoimmun Rev 14:601\u2013608. https:\/\/doi.org\/10.1016\/j.autrev.2015.02.008","journal-title":"Autoimmun Rev"},{"key":"6992_CR23","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3969\/j.issn.1006-2238.2020.11.029","volume":"55","author":"W Jiang","year":"2020","unstructured":"Jiang W, He D, Hu J et al (2020) Observation on the efficacy and safety of Taitaxipu in the treatment of moderate to severe active systemic lupus erythematosus. Jiangxi Med J 55:1637\u20131641. https:\/\/doi.org\/10.3969\/j.issn.1006-2238.2020.11.029. 1671, (in Chinese)","journal-title":"Jiangxi Med J"},{"key":"6992_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1600-0609.1998.tb01041.x","volume":"60","author":"E Lipp","year":"1998","unstructured":"Lipp E, von Felten A, Sax H, M\u00fcller D, Berchtold P (1998) Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol 60:283\u2013288. https:\/\/doi.org\/10.1111\/j.1600-0609.1998.tb01041.x","journal-title":"Eur J Haematol"},{"key":"6992_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.1365-2141.2002.03817.x","volume":"119","author":"M Michel","year":"2002","unstructured":"Michel M, Lee K, Piette JC, Fromont P, Schaeffer A, Bierling P, Godeau B (2002) Platelet autoantibodies and lupus-associated thrombocytopenia. Br J Haematol 119:354\u2013358. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03817.x","journal-title":"Br J Haematol"},{"key":"6992_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2249.2006.03122.x","volume":"145","author":"PD Ziakas","year":"2006","unstructured":"Ziakas PD, Routsias JG, Giannouli S, Tasidou A, Tzioufas AG, Voulgarelis M (2006) Suspects in the tale of lupus-associated thrombocytopenia. Clin Exp Immunol 145:71\u201380. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03122.x","journal-title":"Clin Exp Immunol"},{"key":"6992_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.autrev.2013.02.001","volume":"12","author":"K Newman","year":"2013","unstructured":"Newman K, Owlia MB, El-Hemaidi I, Akhtari M (2013) Management of immune cytopenias in patients with systemic lupus erythematosus \u2014 old and new. Autoimmun Rev 12:784\u2013791. https:\/\/doi.org\/10.1016\/j.autrev.2013.02.001","journal-title":"Autoimmun Rev"},{"key":"6992_CR28","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel T, Basta F, Weinmann-Menke J, Schwarting A (2021) B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 20:102736. https:\/\/doi.org\/10.1016\/j.autrev.2020.102736","journal-title":"Autoimmun Rev"},{"key":"6992_CR29","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/0961203320917748","volume":"29","author":"OC Kwon","year":"2020","unstructured":"Kwon OC, Kim Y, Park JH, Park M (2020) Seroconversion to antinuclear antibody negativity and its association with disease flare in patients with systemic lupus erythematosus. Lupus 29:697\u2013704. https:\/\/doi.org\/10.1177\/0961203320917748","journal-title":"Lupus"},{"key":"6992_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","volume":"67","author":"G Bayer","year":"2019","unstructured":"Bayer G, Agier M, Lioger B, Lepelley M, Zenut M, Lanoue M, Maillot F, Jonville-Bera A (2019) Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med 67:59\u201364. https:\/\/doi.org\/10.1016\/j.ejim.2019.06.009","journal-title":"Eur J Intern Med"},{"key":"6992_CR31","doi-asserted-by":"publisher","unstructured":"Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O (2019) Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.01990","DOI":"10.3389\/fimmu.2019.01990"},{"key":"6992_CR32","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, Lisse JR, Mckay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, Mccune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168\u20131178. https:\/\/doi.org\/10.1002\/art.24699","journal-title":"Arthritis Rheum"},{"key":"6992_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/rheumatology\/keg069","volume":"42","author":"SM Sultan","year":"2003","unstructured":"Sultan SM (2003) Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology 42:230\u2013234. https:\/\/doi.org\/10.1093\/rheumatology\/keg069","journal-title":"Rheumatology"},{"issue":"2019","key":"6992_CR34","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstr\u00f8m K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT (2019) update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(2019):736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"6992_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/0961203314532699","volume":"23","author":"M Petri","year":"2014","unstructured":"Petri M, Bechtel B, Dennis G, Shah M, Mclaughlin T, Kan H, Molta C (2014) Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel. Lupus 23:1006\u20131013. https:\/\/doi.org\/10.1177\/0961203314532699","journal-title":"Lupus"},{"key":"6992_CR36","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clinthera.2013.03.001","volume":"35","author":"M Shah","year":"2013","unstructured":"Shah M, Chaudhari S, Mclaughlin TP, Kan HJ, Bechtel B, Dennis GJ, Molta CT (2013) Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. Clin Ther 35:486\u2013497. https:\/\/doi.org\/10.1016\/j.clinthera.2013.03.001","journal-title":"Clin Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06992-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T04:07:52Z","timestamp":1718683672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06992-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6992"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06992-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Medical Ethics Committee of the Affiliated Hospital of North Sichuan Medical College (2023ER180-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients and\/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}